Stock listing

NASDAQ:NEUP Neuphoria Therapeutics Inc. Stock

Home listing (NASDAQ) of Neuphoria Therapeutics Inc.

Follow Neuphoria Therapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:NEUP

$2.35 USD +0.07 (+3.1%)

Close on Nov 20, 2026

Past year -44.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.27 – $2.38 USDNov 20, 2026
Volume
55,960 sharesNov 20, 2026
Market cap
$12.72M USDAt the close on Nov 20, 2026 · price × 5.41M shares outstanding
52-week range
$2.26 – $5.53 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$98,365 USDMedian day 20,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Neuphoria Therapeutics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:NEUP · Home$2.35 USD+0.07 (+3.1%)55,960$2.33$2.38$2.27$2.28Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NEUP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.35+0.07+3.1%$2.33$2.38$2.2755,960
$2.28+0.01+0.4%$2.27$2.405$2.2724,224
$2.27-0.21-8.5%$2.51$2.51$2.2633,724
$2.48-0.07-2.7%$2.47$2.54$2.4523,377
$2.55-0.03-1.2%$2.63$2.635$2.4914,971
$2.58-0.13-4.8%$2.67$2.765$2.5419,500
$2.71+0.02+0.7%$2.675$2.755$2.6734,713
$2.69-0.07-2.5%$2.795$2.81$2.6228,870
$2.76-0.02-0.7%$2.86$2.86$2.7523,995
$2.78+0.01+0.4%$2.732$2.83$2.73219,631
$2.77-0.21-7.0%$2.97$2.975$2.7140,020
$2.98-0.01-0.3%$3.05$3.07$2.9877,554
$2.99-0.05-1.6%$3.05$3.05$2.997,828
$3.04-0.01-0.3%$3.10$3.10$2.9952,454
$3.05-0.01-0.3%$3.10$3.11$3.0470,249
$3.06-0.30-8.9%$3.32$3.32$3.03270,085
$3.36-0.03-0.9%$3.40$3.42$3.3216,063
$3.39+0.01+0.3%$3.38$3.39$3.383,638
$3.38-0.06-1.7%$3.39$3.46$3.35526,699
$3.44-0.04-1.1%$3.46$3.59$3.3773,000
$3.480.000.0%$3.46$3.56$3.464,800
$3.48+0.09+2.7%$3.49$3.54$3.4658,800
$3.39+0.08+2.4%$3.365$3.40$3.3320,800
$3.31+0.01+0.3%$3.24$3.41$3.2439,500
$3.30-0.01-0.3%$3.35$3.41$3.2476,000
$3.31+0.07+2.2%$3.25$3.42$3.2518,700
$3.24-0.15-4.4%$3.32$3.37$3.2444,100
$3.39+0.07+2.1%$3.49$3.49$3.3226,600
$3.32-0.04-1.2%$3.32$3.38$3.3210,000
$3.36+0.01+0.3%$3.33$3.41$3.322,500
$3.35-0.07-2.0%$3.40$3.42$3.3416,500
$3.42-0.03-0.9%$3.40$3.45$3.404,500
$3.450.000.0%$3.45$3.50$3.4316,500
$3.45-0.02-0.6%$3.45$3.50$3.4315,500
$3.47-0.04-1.1%$3.51$3.59$3.4512,600
$3.51-0.05-1.4%$3.525$3.54$3.5014,300
$3.56-0.01-0.3%$3.60$3.615$3.5310,400
$3.57-0.08-2.2%$3.64$3.65$3.5715,000
$3.650.000.0%$3.67$3.69$3.652,900
$3.650.000.0%$3.67$3.67$3.651,300
$3.65-0.03-0.8%$3.67$3.70$3.655,400
$3.68-0.055-1.5%$3.69$3.755$3.6615,500
$3.735+0.025+0.7%$3.73$3.77$3.716,700
$3.71+0.01+0.3%$3.69$3.79$3.6817,900
$3.70-0.015-0.4%$3.712$3.83$3.7021,600
$3.715-0.025-0.7%$3.79$3.79$3.715,300
$3.74-0.04-1.1%$3.72$3.81$3.7236,800
$3.78-0.02-0.5%$3.75$3.80$3.7317,700
$3.80+0.07+1.9%$3.78$3.84$3.7412,400
$3.730.000.0%$3.78$3.78$3.7223,000
$3.73-0.02-0.5%$3.79$3.793$3.7043,000
$3.750.000.0%$3.795$3.865$3.7518,600
$3.75-0.02-0.5%$3.84$3.84$3.7222,600
$3.77+0.01+0.3%$3.74$3.78$3.7321,900
$3.76+0.01+0.3%$3.84$3.84$3.7427,300
$3.75-0.04-1.1%$3.84$3.84$3.7517,900
$3.79+0.03+0.8%$3.73$3.81$3.7320,800
$3.760.000.0%$3.71$3.815$3.7152,200
$3.76-0.01-0.3%$3.72$3.835$3.7229,900
$3.77-0.09-2.3%$3.84$3.90$3.7150,100
$3.860.000.0%$3.86$3.995$3.85441,000
$3.86-0.09-2.3%$3.93$3.96$3.8533,600
$3.95+0.04+1.0%$3.90$4.01$3.9057,900
$3.91-0.04-1.0%$3.98$4.05$3.91179,800
$3.95+0.02+0.5%$3.98$4.00$3.9255,700

Splits

1 split · NASDAQ:NEUP · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
Ticker
NASDAQ:NEUP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Neuphoria Therapeutics Inc. news

Neuphoria Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
7 in the last 12 months · 78 in all · newest Jul 23, 2026 · oldest 2021
Decks
5 decks · latest Jul 24, 2026

Where Neuphoria Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:NEUP · Home listing · This pageNASDAQUnited StatesUSD
BOATS:NEUPBOATSUnited StatesUSD

Valuation

Price/book 0.5× against a median of 1.5×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$6.03M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.61

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Neuphoria Therapeutics Inc. · NASDAQ:NEUPUS$12.72M−US$6.03Mn/an/an/a0.5×n/a0.0×0.61
Tvardi Therapeutics, Inc. · NASDAQ:TVRDUS$13.22M−US$9.05Mn/an/an/a0.9×n/a0.0×1.89
Diamyd Medical AB Class B · OMXSTO:DMYD_BUS$13.22M−US$16.66Mn/a−357×n/a0.6×n/a0.0×n/a
Devonian Health Group, Inc. · TSXV:GSDUS$13.09MUS$12.59Mn/a6.0×n/a2.7×−204.1%0.0×0.12
Bolt Biotherapeutics, Inc. · NASDAQ:BOLTUS$12.80MUS$18.89Mn/a7.5×n/a1.5×n/a2.4×0.52
Avai Bio, Inc. · OTC:AVAIUS$12.79MUS$12.67Mn/an/an/an/an/an/a0.28
Seres Therapeutics, Inc. · NASDAQ:MCRBUS$12.64MUS$30.89Mn/a14.5×n/a0.6×n/a1.7×1.21
Passage Bio, Inc. · NASDAQ:PASGUS$12.61M−US$7.55Mn/an/an/a252×n/a0.0×1.94
Allarity Therapeutics, Inc. · NASDAQ:ALLRUS$12.56MUS$21.48Mn/a61.4×n/an/an/an/a1.40
Lobe Sciences Ltd · CSE:LOBEUS$12.52MUS$8.89Mn/an/an/a9.5×n/a0.0×0.31
Biophytis SA · EURONEXT:ALBPSUS$12.47MUS$19.44Mn/an/an/an/an/an/an/a
Median of the othersUS$12.72MUS$12.63M7.5×1.5×−204.1%0.0×0.87

Forecasts

1 hold · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.

Price target
7.00 USD · Analysts' mean
EPS, year to Jun 2027
-2.43 · 1 analyst

Team and board

Officers

OfficerRole
Spyros PapapetropoulosInterim CEO & Executive Director
Tim CunninghamFractional CFO
Spyridon PapapetropoulosIR & PR

Board

DirectorRole
Alan FisherNon-Executive Chairman
David WilsonNon-Executive Director
Jane RyanNon-Executive Director
Miles DaviesNon-Executive Director
Spyros PapapetropoulosInterim CEO & Executive Director

Events

QuarterResultsShare move
Q1 2027Nov 16, 2026−11.0%
Q4 2026Sep 18, 2026 · After close+0.3%
Q3 2026May 15, 2026 · Before open−7.1%
Q2 2026Feb 17, 2026 · After close+8.9%
Q1 2026Nov 14, 2025−1.1%
Q4 2025Sep 29, 2025 · After close−0.6%
Q3 2025May 20, 2025 · After close+2.4%
Q2 2025Feb 20, 2025−6.7%
Q1 2025Nov 27, 2024+6.0%
Q4 2024Aug 21, 2024−2.3%
All 20 quarters
QuarterResultsShare move
Q3 2024May 29, 2024+1.3%
Q2 2024Feb 22, 2024−8.8%
Q1 2024Nov 29, 2023−9.0%
Q4 2023Aug 23, 2023+25.0%
Q3 2023May 31, 2023+0.9%
Q2 2023Feb 23, 2023+30.3%
Q1 2023Nov 30, 2022+0.1%
Q4 2022Aug 25, 2022+0.3%
Q3 2022Jun 1, 20220.0%
Q2 2022Feb 23, 20220.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck35 slidesJul 24, 2026
Proxy Contest (November 2025)Proxy contest18 slidesNov 26, 2025
Proxy Contest (November 2025)Proxy contest25 slidesNov 25, 2025
Investor Presentation (2025)Investor deck40 slides2025
Bionomics — H.C. Wainwright BIOCONNECT Virtual Conference 2022Conference37 slidesJan 12, 2022

Open Decks

IPO

Went public as BIONOMICS LIMITED/FI. Priced at US$12.35 an ADS on Dec 15, 2021.

Price
US$12.35 an ADS
ADSs offered
1,622,000 American depositary shares
Offering size
US$20 million
Underwriters
Evercore ISI, William Blair, Cantor, Berenberg, H.C. Wainwright & Co. · In the order on the cover
ADSs delivered
On or about Dec 20, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceSep 10, 2021
Filed publiclyNov 22, 2021
Amended twiceNewest Dec 13, 2021
Shares registered with an exchangeDec 13, 2021
Declared effective by the SECDec 15, 2021
Final prospectus, with the priceDec 17, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Dec 17, 2021

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue1.17M15.6M00383.2K927.5K32.1K7.40M11.9M27.1M
Cost of revenue663.0K662.9K663.0K671.5K16.0M1.69M12.1M25.4M24.2M
Gross profit1.17M15.6M-663.0K-671.5K-9.98M-1.27M32.1K2.68M-13.4M2.84M
Research and development3.55M9.01M9.42M13.1M23.3M4.33M4.00M6.29M18.5M18.6M
Selling, general and administrative7.44M7.77M8.47M13.4M7.43M4.24M3.33M6.55M4.97M5.72M
Operating income-16.5M-1.13M-17.9M-22.0M-31.0M-8.96M-6.19M-10.8M-21.3M-13.8M
Depreciation and amortization663.0K662.9K663.0K663.2K1.11M1.28M1.68M1.43M1.68M1.82M
EBITDA-15.8M-466.2K-17.2M-21.3M-29.9M-7.68M-4.52M-9.32M-19.6M-12.0M
Interest expense29.6K26.9K1.08M1.24M1.66M1.51M1.51M
Income before tax-13.6M-838.0K-15.6M-21.5M-31.9M-6.68M-4.14M-6.94M-19.3M-4.79M
Income tax-139.2K-468.4K-87.3K-139.2K-278.8K-140.8K-142.7K-165.8K-853.0K401.6K
Net income-13.5M-369.6K-15.5M-21.4M-22.9M-6.53M-4.89M-6.77M-18.4M-5.19M
Earnings per share, basic-3.06-0.23-18.62-0.02-0.20-0.10-0.11-0.16-0.46-0.13
Earnings per share, diluted-3.06-0.23-18.62-0.02

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents19.9M14.2M12.6M12.1M33.6M21.4M3.15M9.79M18.3M32.9M
Short-term investments327.3K385.2K404.0K422.6K
Receivables813.4K11.9K126.9K426.1K6.78M192.9K40.7K621.0K523.5K7.60M
Inventory121465.4K360.0K327.2K
Current assets21.1M15.0M13.2M13.3M41.8M23.2M5.73M17.6M26.4M41.9M
Property, plant and equipment2.77K1.99K2.52K
Goodwill3.50M8.64M8.69M8.69M12.9M9.32M8.84M8.94M9.16M9.42M
Total assets28.7M28.6M27.6M28.6M65.3M40.8M23.7M37.6M47.8M64.6M
Accounts payable385.6K1.15M2.24M1.44M1.56M772.9K866.8K842.3K2.65M1.46M
Current liabilities756.6K4.22M3.83M2.74M3.36M1.77M5.68M9.67M9.76M10.7M
Total debt34.3K116.3K272.7K582.3K693.5K652.0K8.41M12.0M15.8M14.2M
Total liabilities4.11M9.59M10.2M6.55M8.40M5.01M15.0M25.2M35.3M33.5M
Shareholders' equity24.6M19.0M24.6M22.0M56.9M35.8M8.71M12.4M12.5M31.1M
Shares outstanding5.41M1.98M1.10M1.47B112.8M65.0M45.4M43.4M40.2M40.1M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-12.4M77.2K-14.7M-14.6M-21.8M-5.66M-2.68M-10.9M-15.0M-1.44M
Capital spending-400-0-1.54K-1.10K-5.29K-69.3K-358.1K-247.5K
Free cash flow-12.4M77.2K-14.7M-9.85M-21.8M-5.67M-2.69M-11.0M-15.4M-1.69M
Cash from investing317.4K621.6K-60.3K-134.1K138.4K59.7K953.9K
Cash from financing17.9M1.53M15.1M3.86M27.0M23.7M-3.68M3.05M1.94M-2.08M
Share buybacks-415.5K-48.2K-420.4K
Change in cash5.58M1.60M505.0K-10.8M5.06M18.0M-6.46M-7.67M-13.2M-2.58M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportOct 23, 2026Material contractSEC
SCHEDULE 13G · Big-stake noticeOct 5, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialSep 18, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialSep 18, 2026Meeting noticeSEC
DEF 14A · Proxy statementSep 18, 2026Meeting noticeSEC
10-K · Annual reportSep 18, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 28, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialJul 23, 2026Meeting noticeSEC
8-K · Current reportJul 23, 2026Material contractSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportMay 26, 2026Current reportSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
10-Q · Quarterly reportFeb 17, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 6, 2026Big-stake noticeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
8-K · Current reportJan 7, 2026Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 29, 2025Big-stake noticeSEC
8-K · Current reportDec 18, 2025Current reportSEC
8-K · Current reportDec 17, 2025Meeting outcomeSEC
DFAN14ADec 8, 2025Other filingsSEC
DFAN14ADec 8, 2025Other filingsSEC
DEFA14A · Additional proxy materialDec 8, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialDec 4, 2025Meeting noticeSEC
DFAN14ADec 3, 2025Other filingsSEC
DFAN14ADec 2, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 2, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialDec 1, 2025Meeting noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 28, 2025Big-stake noticeSEC
DFAN14ANov 26, 2025Other filingsSEC
DFRN14ANov 25, 2025Other filingsSEC
DEFA14A · Additional proxy materialNov 25, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialNov 24, 2025Meeting noticeSEC
DEFC14ANov 24, 2025Other filingsSEC
DEFC14ANov 24, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 18, 2025Big-stake noticeSEC
PREC14ANov 14, 2025Other filingsSEC
424B5 · ProspectusNov 14, 2025Offer documentSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
CORRESP · Letter to the SECNov 12, 2025Other filingsSEC
DEFA14A · Additional proxy materialNov 12, 2025Meeting noticeSEC
PREC14ANov 12, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 10, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 5, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 31, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 31, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialOct 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementOct 29, 2025Meeting noticeSEC
8-K · Current reportOct 27, 2025Material contractSEC
424B5 · ProspectusOct 27, 2025Offer documentSEC
SCHEDULE 13D · Big-stake noticeOct 23, 2025Big-stake noticeSEC
4 · Change in ownershipOct 23, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 23, 2025Insider tradeSEC
424B5 · ProspectusOct 20, 2025Offer documentSEC
8-K · Current reportOct 20, 2025Current reportSEC
10-K · Annual reportSep 29, 2025Annual reportSEC
424B5 · ProspectusSep 23, 2025Offer documentSEC
8-K · Current reportSep 16, 2025Current reportSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
424B5 · ProspectusJul 29, 2025Offer documentSEC
8-K · Current reportJul 18, 2025Current reportSEC
8-K · Current reportMay 20, 2025ResultsSEC
10-Q · Quarterly reportMay 20, 2025Quarterly reportSEC
4/A · Change in ownership, amendedMay 19, 2025Insider tradeSEC
NT 10-Q · Late filing noticeMay 15, 2025Explanation requestSEC
4 · Change in ownershipApr 18, 2025Insider tradeSEC
4 · Change in ownershipApr 18, 2025Insider tradeSEC
4 · Change in ownershipApr 18, 2025Insider tradeSEC
4 · Change in ownershipApr 18, 2025Insider tradeSEC
4 · Change in ownershipApr 18, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportFeb 14, 2025Quarterly reportSEC
424B5 · ProspectusFeb 12, 2025Offer documentSEC
424B5 · ProspectusFeb 4, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 30, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 28, 2025Big-stake noticeSEC
CORRESP · Letter to the SECJan 28, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 28, 2025Other filingsSEC
S-8 · Registration statement for employee plansJan 28, 2025Offer documentSEC
S-3 · Registration statementJan 27, 2025Offer documentSEC
8-K · Current reportJan 14, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveJan 10, 2025Other filingsSEC
CORRESP · Letter to the SECJan 7, 2025Other filingsSEC
S-3/A · Registration statement, amendedJan 7, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 30, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveDec 30, 2024Other filingsSEC
8-K · Current reportDec 23, 2024Material contractSEC
POS AM · Amendment to an effective registrationDec 23, 2024Offer documentSEC
POS AM · Amendment to an effective registrationDec 23, 2024Offer documentSEC
15-12GDec 23, 2024Other filingsSEC
8-K · Current reportDec 16, 2024Current reportSEC
8-K · Current reportDec 12, 2024Meeting outcomeSEC
S-3/A · Registration statement, amendedNov 25, 2024Offer documentSEC
UPLOAD · Letter from the SECNov 21, 2024Other filingsSEC
8-K · Current reportNov 21, 2024Material contractSEC
S-3 · Registration statementNov 18, 2024Offer documentSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
DEFA14A · Additional proxy materialNov 13, 2024Meeting noticeSEC
DEF 14A · Proxy statementNov 12, 2024Meeting noticeSEC
8-K · Current reportNov 8, 2024Current reportSEC
8-K · Current reportOct 10, 2024Management or board changeSEC
PRE 14A · Preliminary proxy statementOct 9, 2024Meeting noticeSEC
SC 13D/A · Big-stake notice, amendedOct 7, 2024Big-stake noticeSEC
8-K · Current reportOct 1, 2024Material contractSEC
10-K · Annual reportSep 30, 2024Annual reportSEC
8-K · Current reportJul 16, 2024Current reportSEC
3 · Initial statement of ownershipJul 12, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 8, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 8, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 8, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 8, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 8, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 8, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveJun 27, 2024Other filingsSEC
424B3 · ProspectusJun 26, 2024Offer documentSEC
CORRESP · Letter to the SECJun 24, 2024Other filingsSEC
UPLOAD · Letter from the SECJun 21, 2024Other filingsSEC
F-1 · Registration statementJun 18, 2024Offer documentSEC
6-K · Report of a foreign issuerJun 3, 2024Current reportSEC
6-K · Report of a foreign issuerMar 15, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
UPLOAD · Letter from the SECJan 18, 2024Other filingsSEC
20-F/A · Annual report, amendedJan 17, 2024Annual reportSEC
CORRESP · Letter to the SECJan 11, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 8, 2024Other filingsSEC
6-K · Report of a foreign issuerJan 4, 2024Current reportSEC
6-K · Report of a foreign issuerNov 30, 2023Current reportSEC
6-K · Report of a foreign issuerNov 28, 2023Current reportSEC
6-K · Report of a foreign issuerNov 3, 2023Current reportSEC
SC 13G · Big-stake noticeOct 30, 2023Big-stake noticeSEC
20-F · Annual reportOct 18, 2023Annual reportSEC
6-K · Report of a foreign issuerOct 16, 2023Current reportSEC
SC 13G · Big-stake noticeOct 10, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeSep 29, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerSep 29, 2023Current reportSEC
6-K · Report of a foreign issuerSep 28, 2023Current reportSEC
6-K · Report of a foreign issuerJul 31, 2023Current reportSEC
6-K · Report of a foreign issuerJul 28, 2023Current reportSEC
6-K · Report of a foreign issuerJul 25, 2023Current reportSEC
6-K · Report of a foreign issuerJul 24, 2023Current reportSEC
6-K · Report of a foreign issuerJul 7, 2023Current reportSEC
6-K · Report of a foreign issuerJul 7, 2023Current reportSEC
6-K · Report of a foreign issuerJul 3, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveMay 18, 2023Other filingsSEC
CORRESP · Letter to the SECMay 15, 2023Other filingsSEC
UPLOAD · Letter from the SECMay 11, 2023Other filingsSEC
F-3 · Registration statementMay 5, 2023Offer documentSEC
6-K · Report of a foreign issuerApr 27, 2023Current reportSEC
6-K · Report of a foreign issuerMar 9, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 23, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 23, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 21, 2023Current reportSEC
6-K · Report of a foreign issuerJan 30, 2023Current reportSEC
6-K · Report of a foreign issuerJan 18, 2023Current reportSEC
6-K · Report of a foreign issuerJan 9, 2023Current reportSEC
6-K · Report of a foreign issuerDec 19, 2022Current reportSEC
6-K · Report of a foreign issuerDec 16, 2022Current reportSEC
424B4 · ProspectusNov 18, 2022Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 17, 2022Other filingsSEC
F-1MEF · Registration of more shares for the same offeringNov 16, 2022Offer documentSEC
6-K · Report of a foreign issuerNov 16, 2022Current reportSEC
CORRESP · Letter to the SECNov 14, 2022Other filingsSEC
CORRESP · Letter to the SECNov 14, 2022Other filingsSEC
F-1/A · Registration statement, amendedNov 14, 2022Offer documentSEC
F-1 · Registration statementNov 10, 2022Offer documentSEC
UPLOAD · Letter from the SECNov 4, 2022Other filingsSEC
DRS · Draft registration statementOct 31, 2022Offer documentSEC
6-K · Report of a foreign issuerOct 25, 2022Current reportSEC
6-K · Report of a foreign issuerOct 18, 2022Current reportSEC
6-K · Report of a foreign issuerOct 18, 2022Current reportSEC
20-F · Annual reportOct 14, 2022Annual reportSEC
6-K · Report of a foreign issuerOct 6, 2022Current reportSEC
6-K · Report of a foreign issuerOct 4, 2022Current reportSEC
6-K · Report of a foreign issuerSep 21, 2022Current reportSEC
6-K · Report of a foreign issuerAug 25, 2022Current reportSEC
6-K · Report of a foreign issuerAug 8, 2022Current reportSEC
6-K · Report of a foreign issuerJul 29, 2022Current reportSEC
6-K · Report of a foreign issuerJul 20, 2022Current reportSEC
6-K · Report of a foreign issuerJul 5, 2022Current reportSEC
6-K · Report of a foreign issuerJun 13, 2022Current reportSEC
6-K · Report of a foreign issuerMay 18, 2022Current reportSEC
6-K · Report of a foreign issuerMay 16, 2022Current reportSEC
6-K · Report of a foreign issuerApr 29, 2022Current reportSEC
6-K · Report of a foreign issuerFeb 23, 2022Current reportSEC
SC 13G · Big-stake noticeFeb 14, 2022Big-stake noticeSEC
6-K · Report of a foreign issuerJan 28, 2022Current reportSEC
6-K · Report of a foreign issuerJan 12, 2022Current reportSEC
6-K · Report of a foreign issuerJan 4, 2022Current reportSEC
6-K · Report of a foreign issuerJan 3, 2022Current reportSEC
SC 13D · Big-stake noticeDec 30, 2021Big-stake noticeSEC
6-K · Report of a foreign issuerDec 22, 2021Current reportSEC
S-8 · Registration statement for employee plansDec 20, 2021Offer documentSEC
424B4 · ProspectusDec 17, 2021Offer documentSEC

This page holds 200 of 421 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Neuphoria Therapeutics Inc.’s releases · as of Sep 17, 2026

Common shares
5,411,334
Fully diluted
5,411,334

Fully diluted

LineSharesAs of
Common shares5,411,334Sep 17, 2026

Share count over time

CountShares
Sep 17, 20265,411,334

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Lynx1 Capital Management LP875K16.2%US$3.12MSep 30, 2026
AdvisorShares Investments LLC313K5.8%US$1.11MSep 30, 2026
Vanguard207K3.8%US$738KSep 30, 2026
Shay Capital LLC130K2.4%US$463KSep 30, 2026
Geode Capital50,6360.94%US$180KSep 30, 2026
Ikarian Capital, LLC47,4430.88%US$169KSep 30, 2026
Citadel44,0450.81%US$157KSep 30, 2026
ADAR1 Capital Management, LLC30,0000.55%US$107KSep 30, 2026
Jane Street18,1710.34%US$64,688Sep 30, 2026
Susquehanna14,7320.27%US$52,446Sep 30, 2026
All 18 holders
HolderSharesOf the companyValueAs of
Boothbay Fund Management, LLC14,0000.26%US$49,840Sep 30, 2026
Gts Securities LLC11,4870.21%US$40,894Sep 30, 2026
Merck & Co., Inc.10,0270.19%US$35,696Sep 30, 2026
UBS224<0.01%US$797Sep 30, 2026
Morgan Stanley58<0.01%US$207Sep 30, 2026
Allworth Financial LP41<0.01%US$146Sep 30, 2026
Fidelity16<0.01%US$57Sep 30, 2026
Barclays3<0.01%US$11Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
AdvisorShares Psychedelics ETF253K4.7%US$1.11MJun 30, 2026
Vanguard Total Stock Market Index Fund110K2.0%US$481KJun 30, 2026
Vanguard Extended Market Index Fund63,3171.2%US$277KJun 30, 2026
Fidelity Extended Market Index Fund31,5460.58%US$168KMay 31, 2026
Fidelity Series Total Market Index Fund8,0360.15%US$42,671May 31, 2026
Fidelity Nasdaq Composite Index Fund2,4270.04%US$12,887May 31, 2026
Fidelity Total Market Index Fund2,0010.04%US$10,625May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Lynx1 Capital Management LP16.30%875KDec 26, 2025Schedule 13D
Shay Capital LLC7.30%172KOct 24, 2025Schedule 13G
AdvisorShares Trust5.78%313KSep 30, 2026Schedule 13G
Apeiron Investment Group Ltd.4.50%72,618Jan 24, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Spyros Papapetropoulos
Other companies: Lipocine Inc. (Director · Since at least Apr 11, 2022); Vigil Neuroscience Inc (Chief Medical Officer · Jan 6, 2022 – Nov 18, 2022 · Past); Adamas Pharmaceuticals Inc (Director · Nov 22, 2020 – Nov 24, 2021 · Past)
President and CEO, Director · Since at least Jul 1, 2024
Timothy M Cunningham
Other companies: Rein Therapeutics, Inc. (See Remarks · May 16, 2024 – May 16, 2024 · Past); Alaunos Therapeutics, Inc. (interim CFO · Feb 17, 2021 – Feb 17, 2021 · Past); Organogenesis Holdings Inc. (Chief Financial Officer · Dec 10, 2018 – Apr 22, 2020 · Past)
Chief Financial Officer · Jul 1, 2024 – Jul 1, 2024 · Past
Aaron N. D. Weaver
Other companies: Interactive Strength Inc. (Non-Employee Director · Since at least Apr 27, 2023)
Director · Jul 1, 2024 – Jul 1, 2024 · Past
Tim Cunningham
Other companies: Rein Therapeutics, Inc. (Interim Chief Financial Officer · Since at least Nov 4, 2026)
Fractional CFO · Since at least Nov 4, 2026
Alan FisherNon-Executive Chairman · Since at least Jul 1, 2024
David WilsonNon-Executive Director · Since at least Jul 1, 2024
Jane RyanNon-Executive Director · Since at least Apr 16, 2025
Miles DaviesNon-Executive Director · Since at least Dec 8, 2025
Peter Miles Winston DaviesDirector · Since at least Jul 1, 2024
Spyridon PapapetropoulosIR & PR · Since at least Dec 8, 2025

Open People

Log in to ask 6ix AI your own questions about Neuphoria Therapeutics Inc.